Nadia Chouaki

2.8k total citations · 2 hit papers
48 papers, 1.7k citations indexed

About

Nadia Chouaki is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nadia Chouaki has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 8 papers in Surgery. Recurrent topics in Nadia Chouaki's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Nadia Chouaki is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (19 papers) and Lung Cancer Diagnosis and Treatment (19 papers). Nadia Chouaki collaborates with scholars based in France, United States and Germany. Nadia Chouaki's co-authors include Carla Visseren‐Grul, Filippo de Marinis, Jean-Louis Pujol, William J. John, Luis Paz‐Ares, Michael Thomas, Mircea Dediu, Annamaria H. Zimmermann, Paolo Bidoli and Symantha Melemed and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Nadia Chouaki

46 papers receiving 1.7k citations

Hit Papers

2 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

2012 447 citations Luis Paz‐Ares, Filippo de Marinis et al. The Lancet Oncology profile →
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

2013 438 citations Luis Paz‐Ares, Filippo de Marinis et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nadia Chouaki France	19	1.3k	1.3k	226	210	200	48	1.7k
Epaminontas Samantas Greece	18	621 0.5×	857 0.7×	248 1.1×	181 0.9×	232 1.2×	62	1.2k
Josiane Otto France	20	906 0.7×	1.1k 0.9×	228 1.0×	259 1.2×	175 0.9×	59	1.6k
E.H. Tan Singapore	8	2.0k 1.5×	1.8k 1.4×	544 2.4×	367 1.7×	260 1.3×	23	2.4k
Patrick Peterson United States	21	2.2k 1.7×	1.8k 1.4×	472 2.1×	310 1.5×	166 0.8×	55	2.6k
Cristian Villanueva France	16	508 0.4×	706 0.6×	229 1.0×	301 1.4×	127 0.6×	54	1.2k
Cesare Gridelli Italy	18	2.4k 1.8×	2.1k 1.7×	527 2.3×	270 1.3×	179 0.9×	37	2.9k
Christine K. Gause United States	14	523 0.4×	1.6k 1.2×	379 1.7×	245 1.2×	336 1.7×	38	2.0k
Hideyuki Ohshimo Japan	13	709 0.5×	1.0k 0.8×	284 1.3×	112 0.5×	317 1.6×	17	1.4k
Christine Ciunci United States	12	671 0.5×	851 0.7×	84 0.4×	169 0.8×	121 0.6×	45	1.1k
Saulius Cicėnas Lithuania	12	1.4k 1.0×	1.1k 0.9×	320 1.4×	230 1.1×	137 0.7×	45	1.7k

Countries citing papers authored by Nadia Chouaki

Since Specialization

Citations

This map shows the geographic impact of Nadia Chouaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nadia Chouaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nadia Chouaki more than expected).

Fields of papers citing papers by Nadia Chouaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nadia Chouaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nadia Chouaki. The network helps show where Nadia Chouaki may publish in the future.

Co-authorship network of co-authors of Nadia Chouaki

This figure shows the co-authorship network connecting the top 25 collaborators of Nadia Chouaki. A scholar is included among the top collaborators of Nadia Chouaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nadia Chouaki. Nadia Chouaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blancas, Isabel, Jessica Grosjean, R. Pedersini, et al.. (2024). Abemaciclib for treating patients with HR+/HER2- metastatic breast cancer: a real-world study in France, Italy and Spain. Future Oncology. 20(31). 2371–2384.

Goetz, Matthew P., Meena Okera, Hans Wildiers, et al.. (2021). Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Research and Treatment. 186(2). 417–428. 34 indexed citations

Pivot, Xavier, et al.. (2021). Real-world study on HR+, HER2−, node-positive, high-risk early breast cancer (EBC) in France: patient profiles, management and treatment patterns. The Breast. 56. S37–S38. 1 indexed citations

Brade, Anthony, Frederik Wenz, Friederike Koppe, et al.. (2018). Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial. International Journal of Radiation Oncology*Biology*Physics. 101(4). 927–934. 25 indexed citations

Reck, Martin, Mark A. Socinski, Aleksandra Szczęsna, et al.. (2016). The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours. Value in Health. 19(7). A748–A749. 1 indexed citations

Thatcher, N., T-E. Ciuleanu, Rodryg Ramlau, et al.. (2015). Subgroup Analysis of Elderly Patients in Squire: a Randomized, Multicenter, Open-Label, Phase Iii Study of Necitumumab (N) Plus Gemcitabine-Cisplatin (GC) Chemotherapy Versus Gc Alone in First-Line Treatment of Patients (PTS) with Stage Iv Squamous Non-Small Cell Lung Cancer (SQ-NSCLC). Annals of Oncology. 26. i29–i29. 3 indexed citations

Scagliotti, Giorgio V., Cesare Gridelli, Filippo de Marinis, et al.. (2014). Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Lung Cancer. 85(3). 408–414. 18 indexed citations

Gridelli, Cesare, Filippo de Marinis, Michael Thomas, et al.. (2014). Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. Journal of Thoracic Oncology. 9(7). 991–997. 40 indexed citations

Pérol, M., Tudor–Eliade Ciuleanu, Óscar Arrieta, et al.. (2014). REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.. Journal of Clinical Oncology. 32(15_suppl). LBA8006–LBA8006. 2 indexed citations

10.

Reck, Martin, Mark A. Socinski, Alexander Luft, et al.. (2014). Quality-Of-Life (Qol), Tolerability, and Supportive Care Results: Necitumumab Phase 3 Squire Study. Annals of Oncology. 25. iv445–iv445. 1 indexed citations

11.

Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2013). PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 31(23). 2895–2902. 438 indexed citations breakdown →

12.

Driesen, Peter, et al.. (2013). A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 5(3). 159–168. 8 indexed citations

13.

Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2012). PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(18_suppl). LBA7507–LBA7507. 14 indexed citations

14.

Gridelli, Cesare, Filippo de Marinis, Jean-Louis Pujol, et al.. (2012). Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 7(11). 1713–1721. 44 indexed citations

15.

Paz‐Ares, Luis, Filippo de Marinis, Mircea Dediu, et al.. (2012). Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. The Lancet Oncology. 13(3). 247–255. 447 indexed citations breakdown →

16.

Chiappori, Alberto, Gerold Bepler, Fabrice Barlési, et al.. (2010). Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 5(3). 369–375. 37 indexed citations

17.

Morschhauser, Franck, Stéphane Depil, Éric Jourdan, et al.. (2006). Phase II study of gemcitabine–dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Annals of Oncology. 18(2). 370–375. 34 indexed citations

18.

Viret, F., Marc Ychou, D. Lepillé, et al.. (2004). Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. Journal of Clinical Oncology. 22(14_suppl). 4118–4118. 28 indexed citations

19.

Hasbini, Ali, Abderrahim Fandi, Nadia Chouaki, et al.. (1999). Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngealtype. Annals of Oncology. 10(4). 421–425. 42 indexed citations

20.

Couteau, C., Nadia Chouaki, Serge Leyvraz, et al.. (1999). A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. British Journal of Cancer. 81(3). 457–462. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact